ORGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Organogenesis Holdings Inc (ORGO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has demonstrated exceptional financial growth in the latest quarter, the technical indicators and options data suggest limited immediate upside potential. Additionally, the lack of significant positive catalysts and the bearish stock trend forecast do not support an aggressive entry at this time.
The MACD is slightly positive but contracting, indicating limited momentum. RSI is neutral at 33.941, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 2.314), but the overall technical outlook is neutral.
The company reported strong financial growth in 2025/Q4, with revenue up 78.13% YoY, net income up 497.82% YoY, and EPS up 400% YoY. Gross margin also improved to 77.87%.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Analysts lowered the price target from $9 to $8, citing a 'new economic reality.' Stock trend analysis predicts a high probability of short-term declines (-1.73% next day, -3.98% next week, -11.52% next month).
In 2025/Q4, the company achieved remarkable financial growth: Revenue increased to $225.6M (up 78.13% YoY), Net Income rose to $35.1M (up 497.82% YoY), EPS increased to $0.25 (up 400% YoY), and Gross Margin improved to 77.87% (up 3.17% YoY).
BTIG maintains a Buy rating but lowered the price target from $9 to $8, reflecting a more cautious outlook due to economic conditions despite strong quarterly performance.
